Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma

References

• Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2(494–503):1–516. doi:10.1038/ncpneuro009616932508
   PubMedGoogle Scholar
• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 4):v1–63. doi:10.1093/neuonc/nou223
   PubMedGoogle Scholar
• Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18:195–205. doi:10.1093/neuonc/nov17226323609
   PubMed Web of Science ®Google Scholar
• Lee YH, Martin-Orozco N, Zheng P, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27:1034–1045. doi:10.1038/cr.2017.9028685773
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi:10.1038/nrc323922437870
   PubMed Web of Science ®Google Scholar
• Chmielowski B. Ipilimumab: A first-in-class T-cell potentiator for metastatic melanoma. J Skin Cancer. 2013;2013:423829. doi:10.1155/2013/42382923738073
   PubMedGoogle Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–144. doi:10.1056/NEJMoa130513323724846
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133. doi:10.1056/NEJMoa130236923724867
   PubMed Web of Science ®Google Scholar
• Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009;229:126–144. doi:10.1111/j.1600-065X.2009.00771.x19426219
   PubMed Web of Science ®Google Scholar
• Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6:3479–3492. doi:10.18632/oncotarget.298025682878
   PubMed Web of Science ®Google Scholar
• Qiu XY, Hu DX, Chen WQ, et al. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1754–1769. doi:10.1016/j.bbadis.2018.03.00229510196
   PubMed Web of Science ®Google Scholar
• Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003;63:7462–7467.14612546
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17:1064–1075. doi:10.1093/neuonc/nou30725355681
   PubMed Web of Science ®Google Scholar
• Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget. 2017;8:91779–91794. doi:10.18632/oncotarget.2158629207684
   PubMedGoogle Scholar
• Rider CC, Mulloy B. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem J. 2010;429:1–12. doi:10.1042/BJ2010030520545624
   PubMed Web of Science ®Google Scholar
• Varadaraj A, Patel P, Serrao A, et al. Epigenetic regulation of GDF2 suppresses anoikis in ovarian and breast epithelia. Neoplasia. 2015;17:826–838. doi:10.1016/j.neo.2015.11.00326678910
   PubMed Web of Science ®Google Scholar
• Margheri F, Schiavone N, Papucci L, et al. GDF5 regulates TGFß-dependent angiogenesis in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGFß peptides. PLoS One. 2012;7:e50342. doi:10.1371/journal.pone.005034223226264
   PubMed Web of Science ®Google Scholar
• Du P, Ye L, Li H, Ruge F, Yang Y, Jiang WG. Growth differentiation factor-9 expression is inversely correlated with an aggressive behaviour in human bladder cancer cells. Int J Mol Med. 2012;29:428–434. doi:10.3892/ijmm.2011.85822159313
   PubMed Web of Science ®Google Scholar
• Li Q, Ling Y, Yu L. GDF3 inhibits the growth of breast cancer cells and promotes the apoptosis induced by Taxol. J Cancer Res Clin Oncol. 2012;138:1073–1079. doi:10.1007/s00432-012-1213-322488170
   PubMed Web of Science ®Google Scholar
• Lu X, He X, Su J, et al. EZH2-mediated epigenetic suppression of GDF15 predicts a poor prognosis and regulates cell proliferation in non-small-cell lung cancer. Mol Ther Nucleic Acids. 2018;12:309–318. doi:10.1016/j.omtn.2018.05.01630195769
   PubMedGoogle Scholar
• Li S, Ma YM, Zheng PS, Zhang P. GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2. J Exp Clin Cancer Res. 2018;37:80. doi:10.1186/s13046-018-0744-029636108
   PubMed Web of Science ®Google Scholar
• Codo P, Weller M, Kaulich K, et al. Control of glioma cell migration and invasiveness by GDF-15. Oncotarget. 2016;7:7732–7746. doi:10.18632/oncotarget.681626741507
   PubMedGoogle Scholar
• Roth P, Junker M, Tritschler I, et al. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res. 2010;16:3851–3859. doi:10.1158/1078-0432.CCR-10-070520534737
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang C, Yuan J, et al. PTK7 regulates Id1 expression in CD44-high glioma cells. Neuro Oncol. 2015;17:505–515. doi:10.1093/neuonc/nou22725204555
   PubMed Web of Science ®Google Scholar
• Li Z, Fu J, Li N, Shen L. Quantitative proteome analysis identifies MAP2K6 as potential regulator of LIFR-induced radioresistance in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 2018;505:274–281. doi:10.1016/j.bbrc.2018.09.02030245131
   PubMed Web of Science ®Google Scholar
• Jun F, Hong J, Liu Q, et al. Epithelial membrane protein 3 regulates TGF-beta signaling activation in CD44-high glioblastoma. Oncotarget. 2017;8:14343–14358. doi:10.18632/oncotarget.1110227527869
   PubMedGoogle Scholar
• Li Z, Li N, Shen L, Fu J. Quantitative proteomic analysis identifies MAPK15 as a potential regulator of radioresistance in nasopharyngeal carcinoma cells. Front Oncol. 2018;8:548. doi:10.3389/fonc.2018.0054830524968
   PubMed Web of Science ®Google Scholar
• Hu X, Chen M, Li Y, Wang Y, Wen S, Jun F. Overexpression of ID1 promotes tumor progression in penile squamous cell carcinoma. Oncol Rep. 2019;41:1091–1100. doi:10.3892/or.2018.691230535485
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. doi:10.1016/j.ccr.2009.12.02020129251
   PubMed Web of Science ®Google Scholar
• Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer. 2017;3:56–71. doi:10.1016/j.trecan.2016.11.00828718426
   PubMed Web of Science ®Google Scholar
• Huang J, Liu F, Liu Z, et al. Immune checkpoint in glioblastoma: promising and challenging. Front Pharmacol. 2017;8:242. doi:10.3389/fphar.2017.0024228536525
   PubMed Web of Science ®Google Scholar
• Blumenthal DT, Yalon M, Vainer GW, et al. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol. 2016;129:453–460. doi:10.1007/s11060-016-2190-127377654
   PubMed Web of Science ®Google Scholar
• Carter T, Shaw H, Cohn-Brown D, Chester K, Mulholland P. Ipilimumab and bevacizumab in glioblastoma. Clin Oncol (R Coll Radiol). 2016;28:622–626. doi:10.1016/j.clon.2016.04.04227169593
   PubMed Web of Science ®Google Scholar
• Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19:3165–3175. doi:10.1158/1078-0432.CCR-12-331423613317
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111–122. doi:10.1016/j.immuni.2007.05.01617629517
   PubMed Web of Science ®Google Scholar
• Garber ST, Hashimoto Y, Weathers SP, et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016;18:1357–1366. doi:10.1093/neuonc/now13227370400
   PubMed Web of Science ®Google Scholar
• Baral A, Ye HX, Jiang PC, Yao Y, Mao Y. B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients. Oncol Lett. 2014;8:1195–1201. doi:10.3892/ol.2014.226825120686
   PubMed Web of Science ®Google Scholar
• Liu Y, Carlsson R, Ambjorn M, et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci. 2013;33:14231–14245. doi:10.1523/JNEUROSCI.5812-12.201323986257
   PubMed Web of Science ®Google Scholar
• Shnaper S, Desbaillets I, Brown DA, et al. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer. 2009;125:2624–2630. doi:10.1002/ijc.2463919521960
   PubMed Web of Science ®Google Scholar
• Rogers TJ, Christenson JL, Greene LI, et al. Reversal of triple-negative breast cancer EMT by miR-200c decreases tryptophan catabolism and a program of immunosuppression. Mol Cancer Res. 2019;17:30–41. doi:10.1158/1541-7786.MCR-18-024630213797
   PubMed Web of Science ®Google Scholar
• Liu H, Liu J, Si L, Guo C, Liu W, Liu Y. GDF-15 promotes mitochondrial function and proliferation in neuronal HT22 cells. J Cell Biochem. 2019. doi:10.1002/jcb.28339
   Google Scholar
• Li YL, Chang JT, Lee LY, et al. GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular reactive oxygen species via a SMAD-associated signaling pathway. Oncotarget. 2017;8:1508–1528. doi:10.18632/oncotarget.1364927903972
   PubMedGoogle Scholar
• Qian J, Wang C, Wang B, et al. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation. 2018;15:290. doi:10.1186/s12974-018-1220-730333036
   PubMed Web of Science ®Google Scholar
• Silginer M, Nagy S, Happold C, Schneider H, Weller M, Roth P. Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. Neuro Oncol. 2017;19:1338–1349. doi:10.1093/neuonc/nox05128475775
   PubMed Web of Science ®Google Scholar